{"id":"continuation-of-oxytocin-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Uterine hyperstimulation"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Water intoxication (with prolonged high-dose infusion)"},{"rate":null,"effect":"Fetal bradycardia"}]},"_chembl":{"chemblId":"CHEMBL4303358","moleculeType":"Small molecule","molecularWeight":"1007.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxytocin acts as an agonist at oxytocin receptors located on uterine smooth muscle and mammary gland myoepithelial cells. Upon receptor binding, it triggers calcium influx and increases intracellular calcium concentration, leading to sustained uterine contractions during labor and the postpartum period. It also facilitates milk ejection by contracting mammary tissue during lactation.","oneSentence":"Oxytocin is a peptide hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during labor and postpartum hemorrhage management.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:44.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Induction or augmentation of labor"},{"name":"Prevention and treatment of postpartum hemorrhage"},{"name":"Management of incomplete or inevitable abortion"}]},"trialDetails":[{"nctId":"NCT03991091","phase":"PHASE4","title":"Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-01-17","conditions":"Neonatal Morbidity","enrollment":2459},{"nctId":"NCT06403982","phase":"NA","title":"The Influence of Oxytocin on Intrapartum Fetal Well-being and Delivery Outcomes in Patients Receiving Epidural Analgesia","status":"ENROLLING_BY_INVITATION","sponsor":"Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland","startDate":"2024-05-06","conditions":"Uterine Contraction, Oxytocin, Labor Progress","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"continuation of oxytocin administration","genericName":"continuation of oxytocin administration","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxytocin is a peptide hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during labor and postpartum hemorrhage management. Used for Induction or augmentation of labor, Prevention and treatment of postpartum hemorrhage, Management of incomplete or inevitable abortion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}